Stockscreener 앱 받기
6.38
1.85%
-0.12
시간 외 거래:
6.38
전일 마감가:
$6.50
열려 있는:
$6.43
하루 거래량:
3.24M
Relative Volume:
1.16
시가총액:
$1.02B
수익:
$418.84M
순이익/손실:
$-1.60M
주가수익비율:
-619.42
EPS:
-0.0103
순현금흐름:
$69.77M
1주 성능:
-2.74%
1개월 성능:
-4.06%
6개월 성능:
-44.43%
1년 성능:
-40.32%
1일 변동 폭
$6.295
$6.67
1주일 범위
$6.295
$6.80
52주 변동 폭
$6.04
$15.38
Certara Inc Stock (CERT) Company Profile
명칭
Certara Inc
전화
(415) 237-8272
주소
4 RADNOR CORPORATE CENTER, SUITE 350, RADNOR
Compare CERT vs VEEV, TEM, BTSG, HQY, MMED
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CERT
Certara Inc
|
6.38 | 1.03B | 418.84M | -1.60M | 69.77M | -0.0103 |
|
VEEV
Veeva Systems Inc
|
185.59 | 30.25B | 3.20B | 908.91M | 1.42B | 5.4155 |
|
TEM
Tempus Ai Inc
|
48.74 | 8.70B | 1.27B | -245.03M | -245.36M | -1.4071 |
|
BTSG
Brightspring Health Services Inc
|
43.99 | 8.27B | 12.91B | 104.80M | 394.69M | 0.8769 |
|
HQY
Healthequity Inc
|
81.13 | 6.80B | 1.31B | 215.20M | 408.32M | 2.4627 |
|
MMED
Minimed Group Inc
|
17.11 | 4.71B | 0 | 0 | 0 | 0.00 |
Certara Inc Stock (CERT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-06 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2026-02-27 | 다운그레이드 | Craig Hallum | Buy → Hold |
| 2026-01-06 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-11-21 | 개시 | Rothschild & Co Redburn | Buy |
| 2025-11-13 | 개시 | BMO Capital Markets | Market Perform |
| 2025-09-29 | 개시 | Craig Hallum | Buy |
| 2025-07-03 | 재개 | Morgan Stanley | Equal-Weight |
| 2025-05-08 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2025-02-27 | 개시 | TD Cowen | Buy |
| 2024-09-27 | 업그레이드 | UBS | Neutral → Buy |
| 2024-04-10 | 업그레이드 | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2024-04-04 | 개시 | JMP Securities | Mkt Perform |
| 2024-02-26 | 개시 | Leerink Partners | Market Perform |
| 2023-12-07 | 개시 | UBS | Neutral |
| 2023-12-05 | 개시 | KeyBanc Capital Markets | Sector Weight |
| 2023-08-22 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-08-10 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-04-12 | 개시 | Stephens | Overweight |
| 2023-04-03 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2022-12-14 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2022-09-08 | 개시 | Berenberg | Buy |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-07-01 | 개시 | Piper Sandler | Overweight |
| 2022-01-11 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-08-05 | 재개 | Credit Suisse | Neutral |
| 2021-07-23 | 개시 | Robert W. Baird | Outperform |
| 2021-03-03 | 개시 | Barclays | Overweight |
| 2021-01-06 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-01-05 | 개시 | BofA Securities | Buy |
| 2021-01-05 | 개시 | Credit Suisse | Neutral |
| 2021-01-05 | 개시 | Jefferies | Hold |
| 2021-01-05 | 개시 | William Blair | Outperform |
모두보기
Certara Inc 주식(CERT)의 최신 뉴스
Market Wrap: Can Certara Inc lead its sector in growthWeekly Profit Recap & High Yield Equity Trading Tips - baoquankhu1.vn
CERT SEC FilingsCertara, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Assessing Certara (CERT) Valuation After FDA PBPK Milestone And New Biosimulation Software Launches - simplywall.st
Certara, Inc. $CERT is ArrowMark Colorado Holdings LLC's 5th Largest Position - MarketBeat
Is Certara (CERT) Offering Opportunity After Prolonged Share Price Weakness - Yahoo Finance
Topline Capital Management LLC Purchases Shares of 546,471 Certara, Inc. $CERT - MarketBeat
Brown Brothers Harriman & Co. Has $46 Million Holdings in Certara, Inc. $CERT - MarketBeat
Alpha Wave Global LP Takes Position in Certara, Inc. $CERT - MarketBeat
Certara Conference: 2025 revenue hits guidance, EBITDA margin tops range as Q4 software bookings slip - MarketBeat
Certara Details 2026 Outlook at Leerink Conference as Software Bookings Slow, AI Push Builds - Yahoo Finance
Certara (CERT) Stock Analysis Report | Ratings, Financials & Performance - Benzinga Japan
Avoiding Lag: Real-Time Signals in (CERT) Movement - Stock Traders Daily
Certara at Barclays Healthcare Conference: Strategic Growth and AI Integration - Investing.com South Africa
Dixon Mitchell Investment Counsel Inc. Purchases Shares of 866,380 Certara, Inc. $CERT - MarketBeat
Certara at Leerink Conference: Strategic Moves Amid Challenges By Investing.com - Investing.com South Africa
Certara at Leerink Conference: Strategic Moves Amid Challenges - Investing.com
Certara, Inc. (NASDAQ:CERT) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
How Investors Are Reacting To Certara (CERT) FDA Acceptance Of Simcyp In Place Of Clinical Trials - Sahm
Assessing Certara (CERT) Valuation After FDA PBPK Milestone And Latest Earnings Guidance - Sahm
Certara CEO Resnick Teases Regulatory Services Decision, Phoenix Cloud Push at TD Cowen Conference - Yahoo Finance
Certara appoints Jon Resnick as new CEO; reaffirms FY25 outlook - MSN
Earnings estimates moving higher for Certara (CERT): Time to buy? - MSN
Will Certara Inc. stock outperform international peers2025 EndofYear Setup & Short-Term Trading Alerts - Naître et grandir
CERTCertara Inc Stock Price and Quote - Finviz
Certara, Inc. (CERT): Analysts Assign Equal-Weight Rating Amid Price Stagnation - 富途牛牛
Certara (CERT) Downgraded to Equal-Weight by Barclays | CERT Sto - GuruFocus
Certara's (CERT) Equal Weight Rating Reiterated at Barclays - MarketBeat
Forecasting The Future: 7 Analyst Projections For Certara - Benzinga
Barclays downgrades Certara stock rating on turnaround concerns By Investing.com - Investing.com South Africa
Barclays downgrades Certara stock rating on turnaround concerns - Investing.com Nigeria
Certara at TD Cowen Conference: Strategic Focus and AI Integration By Investing.com - Investing.com Canada
Certara at TD Cowen Conference: Strategic Focus and AI Integration - Investing.com UK
Certara (CERT) Gains FDA Acceptance for PBPK Modeling in Drug Ap - GuruFocus
Certara, Inc. (CERT) Stock Analysis: Exploring a 38% Potential Upside in Health Information Services - DirectorsTalk Interviews
CERT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Certara Simcyp® simulator results replace ten human trials for chronic myeloid leukemia (CML) therapy asciminib - marketscreener.com
Certara Simcyp Simulator Results Replace Ten Human Trials for Chronic Myeloid Leukemia (CML) Therapy asciminib - Bitget
Certara Simcyp® Simulator Results Replace Ten Human Trials for Chronic Myeloid Leukemia (CML) Therapy asciminib - The Manila Times
FDA accepts virtual-patient data so leukemia drug avoids 10 trials - Stock Titan
Certara, Inc. $CERT Stock Holdings Boosted by Roubaix Capital LLC - MarketBeat
Certara Earnings Call: Software Strength Amid Transition - The Globe and Mail
Certara (CERT) director granted 5,547 restricted stock units - Stock Titan
Certara (CERT) director Arjun Bedi submits initial Form 3 insider filing - Stock Titan
Certara (CERT) Is Up 9.6% After Calling 2026 a Transition Year With Slower Growth Guidance - simplywall.st
Assessing Certara (CERT) Valuation After Recent Share Price Volatility - Yahoo Finance
Discipline and Rules-Based Execution in CERT Response - Stock Traders Daily
A Look At Certara (CERT) Valuation After Earnings Miss And 2026 Outlook Reset - simplywall.st
Certara, Inc. Hits 52-Week Low at USD 6.04 Amid Market Struggles - Markets Mojo
Certara (NASDAQ:CERT) Trading 6.1% HigherHere's What Happened - MarketBeat
Certara (CERT) Target Price Lowered by Barclays to $8.00 | CERT Stock News - GuruFocus
Certara (NASDAQ:CERT) Given New $8.00 Price Target at Barclays - MarketBeat
Certara Inc (CERT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
5.94%
자본화:
|
볼륨(24시간):